At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,972 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Study Within the CorEvitas Registry to Evaluate Safety and Effectiveness of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs (bDMARDs) in Japan Among Patients Treated for Moderately to Severely Active Rheumatoid Arthritis
In Brief
An observational study for Arthritis, Rheumatoid. Completed, enrolled 1,972 participants across 1 site.
Detailed Summary
This is a secondary structured database observational study conducted in Rheumatoid Arthritis (RA) patients treated with biologic and nonbiologic DMARDs, including tofacitinib, collected as part of the CorEvitas Japan RA Registry. The data as of September 2022 will be used for this study. The study will include data from March 2016 to the latest data cut available in 2022 for both effectiveness and safety outcomes.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartOct 2022
Primary CompletionOct 2022
TodayJul 2026
First PostedOct 7, 2022
Enrollment StartOct 10, 2022
Primary CompletionOct 10, 2022
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 3.7 years ago